Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025823 | 0.79 | TDP1 (0.47) | KDM4EALDH1A1HSD17B10TSHRCYP2A6 | |
| SCHEMBL14867678 | 0.74 | L3MBTL1 (0.50) | KDM4EATML3MBTL1PGRALDH1A1 | |
| SCHEMBL15821627 | 0.74 | KDM4E (0.55) | KDM4EATML3MBTL1PGRALDH1A1 | |
| SCHEMBL31390726 | 0.74 | KDM4E (0.55) | KDM4EATML3MBTL1PGRALDH1A1 | |
| SCHEMBL17071076 | 0.73 | L3MBTL1 (0.48) | KDM4EATML3MBTL1PGRALDH1A1 | |
| SCHEMBL15309146 | 0.72 | ATM (0.36) | KDM4EATML3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL17071134 | 0.71 | L3MBTL1 (0.47) | KDM4EATML3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL13086954 | 0.71 | ATM (0.56) | KDM4EATML3MBTL1PGRALDH1A1 | |
| SCHEMBL10621020 | 0.71 | L3MBTL1 (0.95) | KDM4EATML3MBTL1PGRALDH1A1 | |
| SCHEMBL28102924 | 0.71 | L3MBTL1 (0.95) | KDM4EATML3MBTL1PGRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1859005-B1 | NOVEL MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2016-04-27 | — | — | EP | disclosed |
| US-8124249-B2 | Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers | MERCK PATENT GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124249-B2 | Derivatives of fused aromatic systems; stability; sublimation stability; easy to purify due to better solubilty; easy reproducibility because do not form isomers | MERCK PATENT GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20080171225-A1 | Novel Materials For Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171225-A1 | Novel Materials For Organic Electroluminescent Devices | MERCK PATENT GMBH (DE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171225-A1 | Novel Materials For Organic Electroluminescent Devices | OR10J3, EML4, TYR | KDM4E 1657/4885ATM 1610/4885L3MBTL1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.